Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.42 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.42 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258024 | 0.91 | NPC1 (0.44) | NPC1ARMAPTNOD2NOD1 | |
| SCHEMBL14099809 | 0.88 | NPC1 (0.44) | NPC1ARMAPTNOD2NOD1 | |
| SCHEMBL26106290 | 0.88 | NPC1 (0.44) | NPC1ARMAPTNOD2NOD1 | |
| SCHEMBL20644785 | 0.88 | AR (0.46) | NPC1ARMAPTNOD2NOD1 | |
| SCHEMBL8100794 | 0.87 | MAPT (0.42) | NPC1MAPTPOLBSMN1; SMN2HTT | |
| SCHEMBL8866941 | 0.87 | NPC1 (0.43) | NPC1ARMAPTNOD2NOD1 | |
| SCHEMBL1844676 | 0.87 | NPC1 (0.43) | NPC1ARMAPTNOD2NOD1 | |
| SCHEMBL8867147 | 0.85 | AR (0.41) | NPC1ARMAPTNOD2NOD1 | |
| SCHEMBL3477514 | 0.84 | AR (0.57) | NPC1ARMAPTNOD2NOD1 | |
| SCHEMBL20644782 | 0.84 | AR (0.41) | NPC1ARMAPTNOD2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064218-B2 | Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2006-06-20 | — | — | US | disclosed |
| US-6906103-B2 | Compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-6849713-B2 | Compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | GLAXOSMITHKLINE LLC | 2003-11-13 | — | — | US | disclosed |
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | SMITHKLINE BEECHAM CORPORATION | 2003-06-26 | — | — | US | disclosed |
| EP-1294713-A2 | COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002000650-A9 | NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECH INC (US) | 2003-03-06 | — | — | WO | disclosed |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | GENELABS TECHNOLOGIES, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002000650-A2 | NOVEL COMPOUNDS POSSESSING ANTIBACTERIAL, ANTIFUNGAL OR ANTITUMOR ACTIVITY | GENELABS TECHNOLOGIES, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119749-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | NPC1 229/4885AR 2365/4885MAPT 4265/4885 |
| US-20020037856-A1 | Novel compounds possessing antibacterial, antifungal or antitumor activity | CYP51A1, MCL1, ERG28 | NPC1 229/4885AR 2365/4885MAPT 4265/4885 |
| US-20030212113-A1 | Novel aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity | TYR, CYP51A1, ODC1 | NPC1 365/4885AR 1181/4885MAPT 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.